Alirocumab

Definition

Alirocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), leading to increased clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream. It is used as an adjunct to diet and maximally tolerated statin therapy for patients who require additional lipid-lowering treatment.

5 Must Know Facts For Your Next Test

1. Alirocumab targets and binds to PCSK9, preventing it from degrading LDL receptors on liver cells.
2. It is administered via subcutaneous injection, typically every two weeks or monthly.
3. Clinical trials have shown that Alirocumab can reduce LDL-C levels by up to 60% in patients with hypercholesterolemia.
4. Common side effects include injection site reactions, nasopharyngitis, and flu-like symptoms.
5. Alirocumab is particularly beneficial for patients with familial hypercholesterolemia or those who are intolerant to statins.

Review Questions

• What is the mechanism of action of Alirocumab?
• How is Alirocumab administered?
• Name two common side effects of Alirocumab.

Related terms

Statins: A class of drugs that inhibit HMG-CoA reductase, reducing cholesterol synthesis in the liver.

PCSK9 Inhibitors: A group of drugs that lower LDL-C levels by preventing PCSK9-mediated degradation of LDL receptors.

Evolocumab: Another monoclonal antibody that inhibits PCSK9, similar to Alirocumab, used for lowering LDL-C levels.